A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Inclusion Criteria:

• Enrollment will be fully sequential by age group, with adolescents (12 to less than 18 years old) enrolling before children (6 to less than 12 years old).

• Have severe areata alopecia (AA) for at least 1 year

• Diagnosis for at least 1 year

• Current AA episode of at least 6 months' duration

• SALT score ≥50% at screening and baseline

• History of trial and failure with at least 1 available treatment (topical or other)for AA

• History of psychological counseling related to AA

• Current episode of severe AA of less than 8 years.

• Note: Participants who have severe AA for ≥8 years may be enrolled if episodesof regrowth, spontaneous or under treatment, have been observed on the affectedareas over the past 8 years.

Exclusion Criteria:

• Primarily "diffuse" type of AA (characterized by diffuse hair shedding).

• Are currently experiencing other forms of alopecia including, but not limited totrichotillomania, telogen effluvium, chemotherapy-induced hair loss, or any otherconcomitant conditions (for example, tinea capitis, psoriasis, lupus erythematosus,or secondary syphilis) that would interfere with evaluations of the effect of studymedication on AA.

• Are largely or wholly incapacitated permitting little or no self-care, such as beingbedridden

• Have uncontrolled arterial hypertension

• Have had major surgery within 8 weeks prior to screening or will require majorsurgery during the study

• Have a history or presence of cardiovascular, respiratory, hepatic,gastrointestinal, endocrine, hematological, neurological, or neuropsychiatricdisorders or any other serious and/or unstable illness that, in the opinion of theinvestigator, could constitute an unacceptable risk when taking IP or interfere withthe interpretation of data.

• Have a positive test for hepatitis B virus (HBV) infection

• Have hepatitis C virus (HCV) infection (positive for anti hepatitis C antibody withconfirmed presence of HCV ribonucleic acid [RNA]).

• Have evidence of human immunodeficiency virus (HIV) infection and/or positive HIVantibodies.